University of Utah Researchers Broaden Understanding of B-Cell Lymphoma (Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma).

A study conducted by researchers at the University of Utah examined the efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the USA. The study included 118 patients, with 95 receiving lonca following 2 L CAR-T and 23 following 3 L CAR-T. Results showed promising outcomes with lonca monotherapy in both 3 L and 4 L settings, including patients resistant to or progressing after CAR-T therapy. The study concluded that lonca was an effective treatment option for R/R DLBCL. [Extracted from the article]